Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study
In this prospective study of HCC surveillance, the GALAD model performed better than individual biomarkers. The cut-off of -1.95 was more useful in our predominantly chronic hepatitis B cohort.
Authors
- Chee‐Kiat Tan (ORCID: https://orcid.org/0000-0001-6992-2319)
- Wei Lun Liou (ORCID: https://orcid.org/0000-0002-9427-0938)
- Hiroyuki Yamada (ORCID: https://orcid.org/0000-0002-5167-3147)
- Pik‐Eu Chang (ORCID: https://orcid.org/0000-0002-2702-8412)
- Thinesh Lee Krishnamoorthy (ORCID: https://orcid.org/0000-0002-5640-1079)
- Siyu Tan (ORCID: https://orcid.org/0000-0002-5331-4594)
- Chin‐Pin Yeo
Institutions
- Singapore General Hospital (SG)
- Fujifilm (Japan) (JP)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1111/jgh.16997
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97